{"protocolSection": {"identificationModule": {"nctId": "NCT01176032", "orgStudyIdInfo": {"id": "CSPP100AES02"}, "secondaryIdInfos": [{"id": "2009-016735-36", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling", "officialTitle": "The \"ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling (ALLMARK)\" Study", "acronym": "ALLMARK"}, "statusModule": {"statusVerifiedDate": "2014-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-06"}, "primaryCompletionDateStruct": {"date": "2013-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-08-02", "studyFirstSubmitQcDate": "2010-08-03", "studyFirstPostDateStruct": {"date": "2010-08-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-04-22", "resultsFirstSubmitQcDate": "2014-07-22", "resultsFirstPostDateStruct": {"date": "2014-07-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-07-22", "lastUpdatePostDateStruct": {"date": "2014-07-24", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess efficacy of aliskiren for reducing circulating levels of biomarkers of left ventricular (LV) remodeling associated with LV hypertrophy (LVH) in hypertensive patients.", "detailedDescription": "Blood pressure was measured 10 weeks after starting treatment (visit 3). All patients who did not achieve the required blood pressure (\\<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication were given 5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg).\n\nThe patient's blood pressure was assessed at visit 4 (week 18) and if it was still not at the required level (\\<140/90 mmHg), the dose of amlodipine was increased to 10 mg.\n\nBlood pressure was again assessed at visit 5 (week 26) and if the required values had not been reached (\\<140/90 mmHg), a 12.5 mg dose of hydrochlorothiazide (HCTZ) was prescribed"}, "conditionsModule": {"conditions": ["Hypertension", "Left Ventricle Hypertrophy"], "keywords": ["Aliskiren", "hypertension", "concentric LVH", "LV remodeling", "LVMI", "biomarkers", "PICP", "CT-1", "MMP-1", "TIMP-1", "AnxA5", "Aldosterone", "Essential hypertension with concentric left ventricle hypertrophy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 74, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren", "type": "EXPERIMENTAL", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (\\<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved.\n\nHCTZ 12.5mg was prescribed at week 26 if the required values (\\<140/90 mmHg) had not been reached.", "interventionNames": ["Drug: Aliskiren", "Drug: Amlodipine", "Drug: Hydrochlorothiazide (HCTZ)"]}, {"label": "Lostaran", "type": "ACTIVE_COMPARATOR", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (\\<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved.\n\nHCTZ 12.5mg was prescribed at week 26 if the required values (\\<140/90 mmHg) had not been reached.", "interventionNames": ["Drug: Losartan", "Drug: Amlodipine", "Drug: Hydrochlorothiazide (HCTZ)"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren", "description": "Aliskiren 300 mg film coated tablets", "armGroupLabels": ["Aliskiren"], "otherNames": ["Rasilez"]}, {"type": "DRUG", "name": "Losartan", "description": "Losartan 100 mg tablets", "armGroupLabels": ["Lostaran"]}, {"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine 5mg was given to patients who did not achieve the required blood pressure (\\<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved.", "armGroupLabels": ["Aliskiren", "Lostaran"]}, {"type": "DRUG", "name": "Hydrochlorothiazide (HCTZ)", "description": "HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (\\<140/90 mmHg) had not been reached.", "armGroupLabels": ["Aliskiren", "Lostaran"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in C-terminal Propeptide of Procollagen Type I (PICP)", "description": "PICP is a measure of blood concentration of procollagen I carboxy-terminal propeptide (PICP), a peptide released from the myocardium when procollagen is converted to type I collagen. This biomarker exhibits good specificity and sensitivity for identifying myocardial fibrosis in hypertension.", "timeFrame": "Baseline, Week 36"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Biomarkers in Heart Disease", "description": "The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease", "description": "The plasma level of biomarker parameter (aldosterone (Aldo)) used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI)", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson)", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method)", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Reduction of Left Ventricular Mass Index (LVMI)", "description": "Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Combination of Aliskiren With Amlodipine in Biomarkers of Heart Disease.", "description": "The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease in Combination of Aliskiren With Amlodipine", "description": "The plasma level of biomarker parameter plasma aldosterone used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI).", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule in Combination of Aliskiren With Amlodipine", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson) in Combination of Aliskiren With Amlodipine", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter in Combination of Aliskiren With Amlodipine", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method) in Combination of Aliskiren With Amlodipine", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)", "timeFrame": "Baseline, Week 36"}, {"measure": "Change From Baseline of LVMI in Combination of Aliskiren With Amlodipine", "description": "Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI", "timeFrame": "Baseline, Week 36"}, {"measure": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Systolic Blood Pressure (SBP)", "description": "The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values", "timeFrame": "Baseline, Week 10,18,26,36"}, {"measure": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Diastolic Blood Pressure (DBP)", "description": "The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values", "timeFrame": "Baseline, Week 10,18,26,36"}, {"measure": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With Satisfactory Response Rate", "description": "Response rate was defined as the proportion of patients with a satisfactory systolic BP response (SBP \\< 140 mmHg or reduction of \u2265 10 mmHg compared to baseline) and a satisfactory diastolic BP response (DBP \\< 90 mmHg or reduction of \u2265 5 mmHg compared to baseline)", "timeFrame": "Baseline, Week10,18,26,36"}, {"measure": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With SBP < 140 mmHg and DBP < 90 mmHg Compared to Baseline", "description": "The control rate was defined as the proportion of patients with SBP \\< 140 mmHg and DBP \\< 90 mmHg compared to baseline", "timeFrame": "Week10,18,26,36"}, {"measure": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Rate of Use of Added Antihypertensive Rescue Drugs", "description": "The rate of use of first and second antihypertensive rescue drugs added was also assessed at all visits after week 2. The rescue drug at week 10 and 18 for those patients not achieving the required BP was amlodipine, Patients who did not achieve the required BP at week 26 were treated with hydrochlorothiazide", "timeFrame": "Baseline, Week 10,18,26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient with hypertension\n* Confirmed concentric left ventricular hypertrophy:\n* LVMI \\> 49.2 g/m2.7 for men and \\>46.7 g/m2.7 for women\n* Relative wall thickness \\> 0.42\n\nExclusion Criteria:\n\n* Sever or secondary HTN\n* LV ejection fraction of \\<40%\n* Patient with compelling indication to ACEIs or ARBs or BB\n* History of myocardial infarction, coronary artery bypass surgery, PTC intervention, TIA or stroke within 6 months of study entry\n* History of collagenopathies, osteopathy\n* eGFR \\<30 ml/min/1,73 m2, serum potassium \u22655,2 mEq/L\n* Morbid obesity (BMI \u2265 42 kg/m2\n* Other protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}, {"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Sanl\u00facar de Barrameda", "state": "Andalucia", "zip": "11540", "country": "Spain", "geoPoint": {"lat": 36.77808, "lon": -6.3515}}, {"facility": "Novartis Investigative Site", "city": "Sevilla", "state": "Andalucia", "zip": "41009", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novartis Investigative Site", "city": "Sevilla", "state": "Andalucia", "zip": "41013", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novartis Investigative Site", "city": "Utrera", "state": "Andalucia", "zip": "41710", "country": "Spain", "geoPoint": {"lat": 37.18516, "lon": -5.78093}}, {"facility": "Novartis Investigative Site", "city": "Burgos", "state": "Castilla y Leon", "zip": "09005", "country": "Spain", "geoPoint": {"lat": 42.34106, "lon": -3.70184}}, {"facility": "Novartis Investigative Site", "city": "Barcelona", "state": "Catalu\u00f1a", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Novartis Investigative Site", "city": "Girona", "state": "Catalu\u00f1a", "zip": "17007", "country": "Spain", "geoPoint": {"lat": 41.98311, "lon": 2.82493}}, {"facility": "Novartis Investigative Site", "city": "L'Hospitalet de Llobregat", "state": "Catalu\u00f1a", "zip": "08907", "country": "Spain", "geoPoint": {"lat": 41.35967, "lon": 2.10028}}, {"facility": "Novartis Investigative Site", "city": "Santa Coloma de Gramanet", "state": "Catalu\u00f1a", "country": "Spain"}, {"facility": "Novartis Investigative Site", "city": "Alicante", "state": "Comunidad Valenciana", "zip": "03004", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "Novartis Investigative Site", "city": "Torrevieja (Alicante)", "state": "Comunidad Valenciana", "zip": "03186", "country": "Spain"}, {"facility": "Novartis Investigative Site", "city": "Valencia", "state": "Comunidad Valenciana", "zip": "46010", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Novartis Investigative Site", "city": "Valencia", "state": "Comunidad Valenciana", "zip": "46014", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Novartis Investigative Site", "city": "Santiago de Compostela", "state": "Galicia", "zip": "15706", "country": "Spain", "geoPoint": {"lat": 42.88052, "lon": -8.54569}}, {"facility": "Novartis Investigative Site", "city": "Galdakano", "state": "Pais Vasco", "zip": "48960", "country": "Spain"}, {"facility": "Novartis Investigative Site", "city": "Bilbao", "state": "Pa\u00eds Vasco", "zip": "48013", "country": "Spain", "geoPoint": {"lat": 43.26271, "lon": -2.92528}}, {"facility": "Novartis Investigative Site", "city": "Vitoria", "state": "Pa\u00eds Vasco", "country": "Spain", "geoPoint": {"lat": 42.84998, "lon": -2.67268}}, {"facility": "Novartis Investigative Site", "city": "Barcelona", "zip": "08006", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Novartis Investigative Site", "city": "Barcelona", "zip": "08025", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28009", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28035", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28040", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28041", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28046", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Santander", "zip": "39008", "country": "Spain", "geoPoint": {"lat": 43.46472, "lon": -3.80444}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "FG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "\"Started\" indicates randomized and safety population", "numSubjects": "37"}, {"groupId": "FG001", "numSubjects": "37"}]}, {"type": "Intention-to-treat (ITT) Population", "achievements": [{"groupId": "FG000", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "37"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "36"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Informed consent withdrawn", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Intention-to-treat (ITT) population", "groups": [{"id": "BG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "BG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "69"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.34", "spread": "9.34"}, {"groupId": "BG001", "value": "58.05", "spread": "10.34"}, {"groupId": "BG002", "value": "59.12", "spread": "9.88"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "20"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "49"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in C-terminal Propeptide of Procollagen Type I (PICP)", "description": "PICP is a measure of blood concentration of procollagen I carboxy-terminal propeptide (PICP), a peptide released from the myocardium when procollagen is converted to type I collagen. This biomarker exhibits good specificity and sensitivity for identifying myocardial fibrosis in hypertension.", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ug/l", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.22", "spread": "20.37"}, {"groupId": "OG001", "value": "-4.25", "spread": "24.80"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biomarkers in Heart Disease", "description": "The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/ml", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"title": "cardiotrophin-1 (CT-1) (n=32,37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-169.15", "spread": "561.51"}, {"groupId": "OG001", "value": "-128.23", "spread": "568.02"}]}]}, {"title": "matrix metalloproteinase-1 (MMP-1) (n=32,37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.93", "spread": "13.33"}, {"groupId": "OG001", "value": "5.51", "spread": "9.58"}]}]}, {"title": "tissue inhibitor of MMPs (TIMP-1) (n=32,37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "spread": "59.18"}, {"groupId": "OG001", "value": "9.15", "spread": "42.58"}]}]}, {"title": "annexin A5 (AnxA5) (n=31,37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.98", "spread": "7.33"}, {"groupId": "OG001", "value": "-1.21", "spread": "4.75"}]}]}, {"title": "NT-proBNP (n=31,34)", "categories": [{"measurements": [{"groupId": "OG000", "value": "18.66", "spread": "165.21"}, {"groupId": "OG001", "value": "-7.55", "spread": "38.11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease", "description": "The plasma level of biomarker parameter (aldosterone (Aldo)) used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI)", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/dl", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.81", "spread": "27.78"}, {"groupId": "OG001", "value": "-7.90", "spread": "76.35"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"title": "LV end-diastolic volume (n=22,34)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.30", "spread": "35.65"}, {"groupId": "OG001", "value": "0.54", "spread": "33.19"}]}]}, {"title": "LV end-systolic volume (n=22,34)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.92", "spread": "12.24"}, {"groupId": "OG001", "value": "0.64", "spread": "21.01"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson)", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"title": "LV ejection fraction Teicholz(n=29,36)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.11"}, {"groupId": "OG001", "value": "0.01", "spread": "0.08"}]}]}, {"title": "LV ejection fraction Simpson(n=22,34)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.14"}, {"groupId": "OG001", "value": "0.00", "spread": "0.11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm/m^2", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.13", "spread": "1.17"}, {"groupId": "OG001", "value": "-0.22", "spread": "0.98"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method)", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm3/m^2", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.55", "spread": "17.94"}, {"groupId": "OG001", "value": "-2.27", "spread": "26.46"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Reduction of Left Ventricular Mass Index (LVMI)", "description": "Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/m^2", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.05", "spread": "18.98"}, {"groupId": "OG001", "value": "-7.96", "spread": "18.69"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Combination of Aliskiren With Amlodipine in Biomarkers of Heart Disease.", "description": "The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/ml", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Aliskiren + Amlodipine", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}, {"id": "OG002", "title": "Losartan", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}, {"id": "OG003", "title": "Losartan + Amlodipine", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "21"}]}], "classes": [{"title": "CT-1(n=15,17,16,21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-289.18", "spread": "608.91"}, {"groupId": "OG001", "value": "-63.23", "spread": "510.91"}, {"groupId": "OG002", "value": "156.89", "spread": "599.29"}, {"groupId": "OG003", "value": "-345.47", "spread": "443.63"}]}]}, {"title": "ANXA5 (n=15,16,16,21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.24", "spread": "3.70"}, {"groupId": "OG001", "value": "-0.74", "spread": "9.73"}, {"groupId": "OG002", "value": "-1.73", "spread": "4.21"}, {"groupId": "OG003", "value": "-0.81", "spread": "5.20"}]}]}, {"title": "MMP-1(n=15,17,16,21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.00", "spread": "10.28"}, {"groupId": "OG001", "value": "4.99", "spread": "15.80"}, {"groupId": "OG002", "value": "5.47", "spread": "7.88"}, {"groupId": "OG003", "value": "5.54", "spread": "10.89"}]}]}, {"title": "TIMP-1 (n=15,17,16,21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.01", "spread": "73.00"}, {"groupId": "OG001", "value": "7.51", "spread": "44.38"}, {"groupId": "OG002", "value": "21.38", "spread": "38.40"}, {"groupId": "OG003", "value": "-0.16", "spread": "44.13"}]}]}, {"title": "NT-proBNP (n=15,16,15,19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.00", "spread": "214.06"}, {"groupId": "OG001", "value": "16.46", "spread": "108.69"}, {"groupId": "OG002", "value": "-3.68", "spread": "23.78"}, {"groupId": "OG003", "value": "-10.60", "spread": "46.91"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease in Combination of Aliskiren With Amlodipine", "description": "The plasma level of biomarker parameter plasma aldosterone used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI).", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/dl", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Aliskiren + Amlodipine", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}, {"id": "OG002", "title": "Losartan", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}, {"id": "OG003", "title": "Losartan + Amlodipine", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.81", "spread": "21.36"}, {"groupId": "OG001", "value": "-5.89", "spread": "32.54"}, {"groupId": "OG002", "value": "-3.12", "spread": "32.45"}, {"groupId": "OG003", "value": "-11.55", "spread": "98.35"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule in Combination of Aliskiren With Amlodipine", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Aliskiren + Amlodipinet", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}, {"id": "OG002", "title": "Losartan", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}, {"id": "OG003", "title": "Losartan + Amlodipine", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "21"}]}], "classes": [{"title": "LV end-diastolic volume (n=11,11,15,19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.60", "spread": "40.43"}, {"groupId": "OG001", "value": "-2.00", "spread": "31.51"}, {"groupId": "OG002", "value": "5.01", "spread": "38.15"}, {"groupId": "OG003", "value": "-2.98", "spread": "29.30"}]}]}, {"title": "LV end-systolic volume (n=11,11, 15,19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.93", "spread": "13.24"}, {"groupId": "OG001", "value": "1.09", "spread": "11.44"}, {"groupId": "OG002", "value": "6.11", "spread": "23.82"}, {"groupId": "OG003", "value": "-3.69", "spread": "17.97"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson) in Combination of Aliskiren With Amlodipine", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Aliskiren + Amlodipinet", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}, {"id": "OG002", "title": "Losartan", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}, {"id": "OG003", "title": "Losartan + Amlodipine", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "21"}]}], "classes": [{"title": "LV ejection fraction Teicholz (n=14,15,16,20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.00", "spread": "0.13"}, {"groupId": "OG002", "value": "-0.00", "spread": "0.07"}, {"groupId": "OG003", "value": "0.01", "spread": "0.09"}]}]}, {"title": "LV ejection fraction Simpson(n=11,11,15,19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.10"}, {"groupId": "OG001", "value": "-0.01", "spread": "0.17"}, {"groupId": "OG002", "value": "-0.02", "spread": "0.12"}, {"groupId": "OG003", "value": "0.02", "spread": "0.11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter in Combination of Aliskiren With Amlodipine", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm/m^2", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Aliskiren + Amlodipinet", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}, {"id": "OG002", "title": "Losartan", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}, {"id": "OG003", "title": "Losartan + Amlodipine", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "17"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.18", "spread": "1.12"}, {"groupId": "OG001", "value": "-0.07", "spread": "1.27"}, {"groupId": "OG002", "value": "-0.19", "spread": "0.96"}, {"groupId": "OG003", "value": "-0.24", "spread": "1.03"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method) in Combination of Aliskiren With Amlodipine", "description": "Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm3/m^2", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Aliskiren + Amlodipinet", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}, {"id": "OG002", "title": "Losartan", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}, {"id": "OG003", "title": "Losartan + Amlodipine", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.88", "spread": "15.74"}, {"groupId": "OG001", "value": "7.78", "spread": "17.14"}, {"groupId": "OG002", "value": "-7.42", "spread": "24.37"}, {"groupId": "OG003", "value": "1.30", "spread": "28.21"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of LVMI in Combination of Aliskiren With Amlodipine", "description": "Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/m2", "timeFrame": "Baseline, Week 36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Aliskiren + Amlodipinet", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}, {"id": "OG002", "title": "Losartan", "description": "losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}, {"id": "OG003", "title": "Losartan + Amlodipine", "description": "5 mg of amlodipine in addition to the study medication in order to reach the required BP (\\<140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (\\<140/90 mmHg) was still not achieved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.68", "spread": "18.95"}, {"groupId": "OG001", "value": "-10.26", "spread": "19.40"}, {"groupId": "OG002", "value": "-3.59", "spread": "13.46"}, {"groupId": "OG003", "value": "-11.46", "spread": "21.71"}]}]}]}, {"type": "SECONDARY", "title": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Systolic Blood Pressure (SBP)", "description": "The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, Week 10,18,26,36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"title": "Baseline, Week 10 (n=30,37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.56", "spread": "12.89"}, {"groupId": "OG001", "value": "-4.03", "spread": "16.93"}]}]}, {"title": "Baseline, Week 18 (n=29,36)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.77", "spread": "12.25"}, {"groupId": "OG001", "value": "-8.44", "spread": "17.30"}]}]}, {"title": "Baseline, Week 26 (n=29,36)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.69", "spread": "15.05"}, {"groupId": "OG001", "value": "-10.40", "spread": "15.74"}]}]}, {"title": "Baseline, Week 36 (n=32,37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.87", "spread": "19.26"}, {"groupId": "OG001", "value": "-8.88", "spread": "15.91"}]}]}]}, {"type": "SECONDARY", "title": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Diastolic Blood Pressure (DBP)", "description": "The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, Week 10,18,26,36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"title": "Baseline, Week 10 (n=30,37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.77", "spread": "10.22"}, {"groupId": "OG001", "value": "-3.15", "spread": "10.97"}]}]}, {"title": "Baseline, Week 18 (n=29,36)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.34", "spread": "10.66"}, {"groupId": "OG001", "value": "-7.07", "spread": "9.98"}]}]}, {"title": "Baseline, Week 26 (n=29,36)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.34", "spread": "11.37"}, {"groupId": "OG001", "value": "-6.94", "spread": "10.10"}]}]}, {"title": "Baseline, Week 36 (n=32,37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.19", "spread": "10.32"}, {"groupId": "OG001", "value": "-6.68", "spread": "9.66"}]}]}]}, {"type": "SECONDARY", "title": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With Satisfactory Response Rate", "description": "Response rate was defined as the proportion of patients with a satisfactory systolic BP response (SBP \\< 140 mmHg or reduction of \u2265 10 mmHg compared to baseline) and a satisfactory diastolic BP response (DBP \\< 90 mmHg or reduction of \u2265 5 mmHg compared to baseline)", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "Baseline, Week10,18,26,36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"title": "Baseline, Week 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "Baseline, Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Baseline, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "27"}]}]}, {"title": "Baseline, Week 36", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "25"}]}]}]}, {"type": "SECONDARY", "title": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With SBP < 140 mmHg and DBP < 90 mmHg Compared to Baseline", "description": "The control rate was defined as the proportion of patients with SBP \\< 140 mmHg and DBP \\< 90 mmHg compared to baseline", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "Week10,18,26,36", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"title": "Control rate at Week 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "13"}]}]}, {"title": "Control rate at Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Control rate at Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "23"}]}]}, {"title": "Control rate at Week 36", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}]}]}, {"type": "SECONDARY", "title": "Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Rate of Use of Added Antihypertensive Rescue Drugs", "description": "The rate of use of first and second antihypertensive rescue drugs added was also assessed at all visits after week 2. The rescue drug at week 10 and 18 for those patients not achieving the required BP was amlodipine, Patients who did not achieve the required BP at week 26 were treated with hydrochlorothiazide", "populationDescription": "Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "Baseline, Week 10,18,26", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks"}, {"id": "OG001", "title": "Lostaran", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"title": "Baseline, Week 10 (amlodipine)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "Baseline, Week 18 (amlodipine)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Baseline, Week 26 (hydrochlorothiazide)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Aliskiren", "description": "Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 37, "otherNumAffected": 12, "otherNumAtRisk": 37}, {"id": "EG001", "title": "Losartan", "description": "Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 37, "otherNumAffected": 16, "otherNumAtRisk": 37}], "seriousEvents": [{"term": "Bronchopneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 37}]}, {"term": "Coronary artery bypass", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 37}]}], "otherEvents": [{"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 37}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 37}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 37}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 37}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 37}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 37}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 37}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 37}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 37}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 37}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 37}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 37}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 37}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 37}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 37}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety"}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "trialandresults.registries@novartis.com", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000006984", "term": "Hypertrophy"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000020763", "term": "Pathological Conditions, Anatomical"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M10035", "name": "Hypertrophy", "asFound": "Hypertrophy", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M22519", "name": "Pathological Conditions, Anatomical", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}